BridgeBio Pharma, Inc. (BBIO)
67.13
+2.19
(+3.37%)
USD |
NASDAQ |
Oct 15, 16:00
67.13
0.00 (0.00%)
After-Hours: 20:00
BridgeBio Pharma Research and Development Expense (Quarterly) : 149.45M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 149.45M |
| March 31, 2026 | 126.64M |
| December 31, 2025 | 116.42M |
| September 30, 2025 | 112.87M |
| June 30, 2025 | 111.23M |
| March 31, 2025 | 111.43M |
| December 31, 2024 | 130.35M |
| September 30, 2024 | 120.44M |
| June 30, 2024 | 114.70M |
| March 31, 2024 | 140.97M |
| December 31, 2023 | 130.23M |
| September 30, 2023 | 125.14M |
| June 30, 2023 | 107.49M |
| March 31, 2023 | 92.86M |
| December 31, 2022 | 90.90M |
| September 30, 2022 | 92.51M |
| June 30, 2022 | 108.40M |
| Date | Value |
|---|---|
| March 31, 2022 | 107.65M |
| December 31, 2021 | 123.75M |
| September 30, 2021 | 104.30M |
| June 30, 2021 | 101.96M |
| March 31, 2021 | 122.56M |
| December 31, 2020 | 90.17M |
| September 30, 2020 | 92.05M |
| June 30, 2020 | 86.60M |
| March 31, 2020 | 68.22M |
| December 31, 2019 | 57.48M |
| September 30, 2019 | 55.28M |
| June 30, 2019 | 52.33M |
| March 31, 2019 | 44.85M |
| December 31, 2018 | 51.20M |
| September 30, 2018 | 31.15M |
| June 30, 2018 | 23.89M |
| March 31, 2018 | 33.83M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Pfizer Inc. | 2.746B |
| Ionis Pharmaceuticals, Inc. | 216.41M |
| BioMarin Pharmaceutical, Inc. | 206.95M |
| Vertex Pharmaceuticals, Inc. | 993.80M |